Modulation Therapeutics logo

News

Modulation Therapeutics Receives Seed Funding through Florida Institute

Tampa-Based Company is Eleventh to Receive Capital through the SCAP Program

Gainesville and Boca Raton, FL — February  14,  2013

The Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with Modulation Therapeutics, an early-stage pharmaceutical company dedicated to the development of novel treatments for multiple myeloma.

http://www.florida-institute.com/news/florida-institute-funds-tampa-based-modulation-therapeutics

Multiple Myeloma Research Foundation Awards Funding to Modulation Therapeutics for Innovative Cancer Treatment

MMRF Biotech Investment Award Bolsters Development of Novel Myeloma Therapies

Norwalk, CT — June 7, 2012

The Multiple Myeloma Research Foundation today announced that it has awarded $500,000 through its Biotech Investment Award program to Modulation Therapeutics.

http://www.themmrf.org/about-the-mmrf/powerful-news/press-releases/multiple-myeloma-research-foundation-mmrf-awards-funding-to-modulation-therapeutics-for-innovative-cancer-treatment.html 

  Latest News

  • Modulation Therapeutics awarded 3rd Phase I SBIR   Aug. 1st, 2013                                                        In collaboration with Cristoph Radar and the Scripps Research Institute, Scripps Florida
  • Modulation Therapeutics receives seed funding      Feb. 14th, 2013                                         Modulation Therapeutics receives seed funding through Florida Institute
  • Modulation Therapeutics awarded 2nd Phase I SBIR   October 25th, 2012                                              Modulation Therapeutics is awarded a Phase I SBIR grant to determine the role of MTI-101 treatment in the bone marrow niche                            
  • Modulation Therapeutics awarded Phase I SBIR September 10, 2012                                                  Modulation Therapeutics is awarded a Phase I SBIR grant to evaluate PK of MT-101 and analogs of MTI-101                                                                                                                                                                 
  • Modulation Therapeutics awarded Florida Bankhead-Coley TTCP Grant                                    June 21, 2012                                                                 Modulation Therapeutics in collaboration with Moffitt Cancer Center is awarded a Bankhead-Coley grant for preclinical testing of MTI-101 in Acute Myeloid Leukemia
  • Multiple Myeloma Research Foundation (MMRF) Awards Funding to Modulation Therapeutics for Innovative Cancer Treatment                     June 7, 2012                                                                 MMRF Biotech Investment Award Bolsters Development of Novel Myeloma Therapies
  • Modulation Therapeutics opens new Research facilities at USF Connect in Tampa FL
    January 9th 2012
    Modulation Therapeutics opens new Research Facilities at USF Connect Research Park in Tampa FL
  • Modulation Therapeutics awarded James and Esther King TTCP Grant
    December 13th 2011                                              Modulation Therapeutics in collaboration with Moffitt Cancer Center is awarded a James and Esther King grant for preclinical testing of MTI-101 in lung cancer models.